<DOC>
	<DOCNO>NCT00167518</DOCNO>
	<brief_summary>The trial test hypothesis intravitreal injection triamcinolone safe efficacious patient clinically significant diabetic macular oedema recalcitrant conventional laser therapy</brief_summary>
	<brief_title>Intravitreal Triamcinolone Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment ( TDMO )</brief_title>
	<detailed_description>Diabetic retinopathy common cause severe loss visual common cause legal blindness individual age 20 65 year developed country . Swelling central retina , “ macular oedema ” commonest cause visual loss diabetic retinopathy . Diabetic macular oedema treat laser coagulation macular area accord establish guideline take account extent leak proximity centre macula , “ fovea ” . This treatment , however , always work inherently destructive . Intravitreal injection crystalline steroid propose new modality treat clinically significant diabetic macular oedema . To determine mean prospective , double-masked , randomised , placebo-controlled trial determine whether intravitreal injection triamcinolone three month focal grid laser photocoagulation clinically significant diabetic macular oedema improve visual acuity eligible eye . OCT use addition visual acuity test objective measurement macular oedema .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Clinically significant diabetic macular oedema involve fovea one eye ( phakic and/or pseudophakic ) persist least 3 month adequate macular photocoagulation . best correct visual acuity affect eye ( ) 6/9 bad Glaucoma uncontrolled control glaucomatous visual field defect Loss vision due cause ( e.g . age related macular degeneration , myopic macular degeneration ) Significant macular ischemia ( FFA ) No useful vision fellow eye Known allergies triamcinolone acetate steroid Patient already systemic treatment &gt; 5mg prednisolone ( equivalent ) daily . Intercurrent severe disease septicaemia Any condition would affect followup photographic documentation ( e.g . geographical , psychosocial , medium opacity )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>Diabetic macular oedema</keyword>
	<keyword>Triamcinolone acetate</keyword>
	<keyword>Intravitreal injection</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>Laser treatment</keyword>
</DOC>